) vaccines division, Sanofi Pasteur, recently announced that
Cdiffense, a phase III program, has been initiated. Sanofi is
working on developing a vaccine for the prevention of primary
symptomatic clostridium difficile infection (CDI). The program
aims to assess the safety, efficacy and immunogenicity of the CDI
In Canada, Sanofi has started enrolling volunteers for the
randomized, observer-blind, placebo-controlled, multi-center,
multi-national (across 17 countries), phase III trial. The trial
will enroll up to 15,000 volunteers aged ≥ 50 years, who have
received systemic antibiotics in the past year and are planning
to be hospitalized or were hospitalized at least twice before.
Earlier this year, Sanofi's vaccine portfolio received a boost
when the European Commission approved its 6-in-1 pediatric
vaccine Hexyon/Hexacima (DTaP-IPV-Hib-HepBvaccine).
The 6-in-1 vaccine is indicated for the prevention of diphtheria,
tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis
and invasive infections caused by haemophilus influenzaetype b in
We note that Sanofi possesses one of the world's leading vaccine
operations, with total sales of €3.9 billion in 2012. The
company's portfolio includes pediatric vaccines, influenza
vaccines, adult and adolescent booster vaccines, meningitis
vaccines, and travel and endemic vaccines. Sanofi also has a
strong position in both seasonal and pre-pandemic influenza
vaccines. Sanofi continues to expand its vaccine business. We
expect a significant ramp in vaccine sales over the next several
Sanofi carries a Zacks Rank #5 (Strong Sell). We are concerned
about generic erosion confronting most of Sanofi's key drugs.
Additionally, recent pipeline failures (oncology candidate
- iniparib and anticoagulant - otamixaban) have put immense
pressure on Sanofi's pipeline.
At present, companies like
Gilead Sciences, Inc.
) look well-positioned with all three being Zacks Rank #1 (Strong
ACTELION LTD (ALIOF): Get Free Report
BIOGEN IDEC INC (BIIB): Free Stock Analysis
GILEAD SCIENCES (GILD): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.